Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • Disclaimer
  • TOC
  • Chapter 14
  • My Images
  • Preface to the Third Edition
  • CME Information
  • Suggested Readings
  • Index
Please subscribe for full access.

Chapter 14

Anxiety Disorders and Anxiolytics

  • Symptom dimensions in anxiety disorders
  • When is anxiety an anxiety disorder?
  • Overlapping symptoms of major depression and anxiety disorders
  • Overlapping symptoms of anxiety disorder subtypes
  • The amygdala and the neurobiology of fear
  • GABA, anxiety, and benzodiazepines
  • GABA-A receptor subtypes
  • Benzodiazepines as positive allosteric modulators (PAMs)
  • Novel GABA anxiolytics
  • Serotonin, stress, and anxiety
  • Stress sensitization
  • Alpha 2 delta ligands as anxiolytics
  • Noradrenergic hyperactivity in anxiety
  • Fear conditioning versus fear extinction
  • Fear extinction means learning to forgive but not to forget
  • Cortico-striatal-thalamic-cortical (CSTS) loops and the neurobiology of worry
  • Treatments for anxiety disorder subtypes
  • Summary

Anxiety Disorders and Anxiolytics

This chapter will provide a brief overview of anxiety disorders and their treatments. Included are descriptions of how the anxiety disorder subtypes overlap with each other and with major depressive disorder. Clinical descriptions and formal criteria for how to diagnose anxiety disorder subtypes are mentioned only in passing. The reader should consult standard reference sources for this material. The discussion here will emphasize how discoveries about the functioning of various brain circuits and neurotransmitters – especially those centered on the amygdala – affect our understanding of fear and worry, which cut across the entire spectrum of anxiety disorders.

The goal of this chapter is to acquaint the reader with ideas about the clinical and biological aspects of anxiety disorders in order to clarify the mechanisms of action of the various treatments for these disorders as they are discussed along the way. Many of these treatments are extensively discussed in previous chapters. For details of mechanisms of anxiolytic agents used also for the treatment of depression (i.e., certain antidepressants),

Save image

FIGURE 14-1 Overlap of MDD and anxiety disorders. Although the core symptoms of anxiety disorders (anxiety and worry) differ from the core symptoms of major depression (loss of interest and depressed mood), there is considerable overlap among the rest of the symptoms associated with these disorders (compare the “anxiety disorders” puzzle on the right to the “MDD” puzzle on the left). For example, fatigue, sleep difficulties, and problems concentrating are common to both types of disorders.

the reader is referred to Chapter 12; for those anxiolytic agents used also as mood stabilizers for the treatment of bipolar disorder (i.e., certain anticonvulsants), the reader is referred to Chapter 13; and for those anxiolytics used as antipsychotics, the place to look is Chapter 10. The discussion in this chapter is at the conceptual level, and not at the pragmatic level. The reader should consult standard drug handbooks (such as Essential Psychopharmacology: Prescriber’s Guide) for details of doses, side effects, drug interactions, and other issues relevant to the prescribing of these drugs in clinical practice.

 
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

back to top

Please wait, page is loading...
 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us